Skip to main content

Lupus (Systemic Lupus Erythematosus) and cannabis in District of Columbia

The state does not list this condition by name, but its statute or regulator permits a certifying physician to add conditions case-by-case. Patients should expect to bring full diagnostic records to the certification visit.

Physician-discretion program
✗ No
LEGAL
Up to 8 oz over any 30-…
POSSESSION
$100/yr
STATE FEE
1–21 d
TIMELINE
Physician-discretion program. The state does not list this condition by name, but its statute or regulator permits a certifying physician to add conditions case-by-case. Patients should expect to bring full diagnostic records to the certification visit.

District of Columbia statute and program

The District of Columbia Medical Cannabis Program is the operating authority for District of Columbia patient certification. The authoritative legal text is: D.C. Official Code §7-1671.01 et seq.: Legalization of Marijuana for Medical Treatment Initiative Act. The program portal is at District of Columbia Medical Cannabis Program.

What the evidence says about cannabis and Lupus (Systemic Lupus Erythematosus)

Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease in which the immune system produces autoantibodies that attack the body's own tissues. Inflammation can affect joints, skin, kidneys, blood, lungs, heart, and the nervous system. Lupus is a relapsing-remitting disease — patients experience flares and periods of relative quiescence.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Lupus (Systemic Lupus Erythematosus) page.

How to qualify in District of Columbia

The District of Columbia Medical Cannabis Program requires the following registration steps for a Lupus (Systemic Lupus Erythematosus) patient (or any qualifying diagnosis):

  1. Self-certification or physician recommendation. Since the 2022 Medical Cannabis Amendment Act, adults 21 and older may self-certify residency and need for medical cannabis without a physician recommendation. Patients under 21 (or anyone preferring the physician path) must obtain a written recommendation from a DC-licensed physician, dentist, APRN, naturopath, or PA registered with the Alcoholic Beverage and Cannabis Administration (ABCA).
  2. Apply through the ABCA online portal. Applications are submitted electronically through the ABCA medical cannabis program portal. Applicants upload a government-issued photo ID (out-of-district IDs accepted under DC reciprocity), proof of residency if applicable, and the physician recommendation when going the certified-patient route.
  3. Pay the registration fee and receive the card. The DC patient registration fee is $100 for one year or $200 for two years; reduced fees of $25 / $50 apply for patients enrolled in Medicaid, SSI, SSDI, or other public assistance under the Medical Cannabis Equity Act. Temporary digital cards are typically issued within several business days; physical cards arrive by mail within roughly two to three weeks.
  4. Purchase from licensed DC medical cannabis dispensaries. DC operates a medical-only retail market (Congress has historically blocked adult-use sales via the Harris Rider appropriations restriction). DC honors out-of-state medical cannabis registrations under its reciprocity statute, so visitors with valid medical registration from any US state may purchase from DC dispensaries with their out-of-state card and ID.
State registration fee
$100
Physician visit (typical)
$0–$200
Certification to card
1–21 days
Out-of-state patients
Eligible
Minors
Eligible with caregiver

For full District of Columbia registration steps, fees, and reciprocity rules, see the District of Columbia cannabis-laws page.

ICD-10 code

A certifying physician documenting Lupus (Systemic Lupus Erythematosus) for the District of Columbia medical cannabis program will typically record ICD-10 M32.9 or SNOMED-CT 55464009 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does District of Columbia list Lupus (Systemic Lupus Erythematosus) as a qualifying condition for medical cannabis?

Not by name, but District of Columbia permits physician discretion. Under District of Columbia Medical Cannabis Program, a certifying physician can add a condition like Lupus (Systemic Lupus Erythematosus) on a case-by-case basis when the physician judges that the patient would benefit from medical cannabis. This is different from a state where the qualifying-condition list is fixed in statute. Whether a particular physician will certify Lupus (Systemic Lupus Erythematosus) depends on the physician's training, the strength of the patient's documentation, and the practitioner's reading of the available evidence — evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). Patients should expect to bring full diagnostic records to the certification visit.

How do I get a District of Columbia medical marijuana card for Lupus (Systemic Lupus Erythematosus)?

Step one is finding a physician licensed in District of Columbia who is registered with District of Columbia Medical Cannabis Program and willing to evaluate Lupus (Systemic Lupus Erythematosus) cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. District of Columbia honors out-of-state medical cards under its reciprocity rules — uncommon, and worth verifying before relying on it. Verify the patient minimum age with the state program before applying. The authoritative source for the current process is the District of Columbia Medical Cannabis Program site at https://abca.dc.gov/page/medical-cannabis-program; the state updates fees, forms, and physician registration rules periodically.

What does the evidence say about cannabis for Lupus (Systemic Lupus Erythematosus)?

For Lupus (Systemic Lupus Erythematosus), evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Lupus (Systemic Lupus Erythematosus) lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Lupus (Systemic Lupus Erythematosus) should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Lupus (Systemic Lupus Erythematosus) and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Lupus (Systemic Lupus Erythematosus); the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. D.C. Official Code §7-1671.01 et seq.: Legalization of Marijuana for Medical Treatment Initiative Actaccessed May 16, 2026
  2. Initiative 71 (2014): Marijuana Legalization Initiativeaccessed May 16, 2026
  3. D.C. Alcoholic Beverage and Cannabis Administration: Medical Cannabis Programaccessed May 16, 2026
  4. Wikipedia: Cannabis in the District of Columbiaaccessed May 16, 2026
  5. NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases: Lupusaccessed May 18, 2026
  6. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 18, 2026

    “Substantial evidence that cannabis or cannabinoids are effective for chronic pain in adults.”

  7. Lupus Foundation of America: Marijuana and Lupusaccessed May 18, 2026
  8. American College of Rheumatology: 2023 Guideline for SLE Management (executive summary)accessed May 18, 2026
  9. MedlinePlus: Systemic lupus erythematosusaccessed May 18, 2026